Wellington Management Group LLP Has $97.81 Million Holdings in AtriCure, Inc. $ATRC

Wellington Management Group LLP raised its holdings in shares of AtriCure, Inc. (NASDAQ:ATRC) by 3.3% during the 2nd quarter, HoldingsChannel reports. The fund owned 3,495,603 shares of the medical device company’s stock after purchasing an additional 113,048 shares during the period. Wellington Management Group LLP owned 0.07% of AtriCure worth $97,807,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Geneos Wealth Management Inc. purchased a new stake in shares of AtriCure in the second quarter worth approximately $37,000. Harbor Investment Advisory LLC acquired a new position in AtriCure in the 2nd quarter valued at approximately $40,000. Allworth Financial LP purchased a new stake in AtriCure in the 2nd quarter worth approximately $43,000. Smartleaf Asset Management LLC lifted its position in AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after buying an additional 429 shares in the last quarter. Finally, Fifth Third Bancorp acquired a new stake in shares of AtriCure during the 1st quarter valued at $51,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Stock Up 1.2%

AtriCure stock opened at $48.92 on Wednesday. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $49.98. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The firm has a market cap of $2.49 billion, a price-to-earnings ratio of 232.96 and a beta of 1.26. The firm has a fifty day moving average price of $38.70 and a two-hundred day moving average price of $32.41.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The firm had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. During the same quarter in the prior year, the company earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, analysts forecast that AtriCure, Inc. will post 0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

ATRC has been the topic of a number of research reports. Canaccord Genuity Group upped their price target on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Weiss Ratings raised AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 19th. Raymond James Financial set a $52.00 target price on AtriCure in a research report on Tuesday, July 21st. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Finally, Zacks Research downgraded AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday, August 24th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, AtriCure presently has a consensus rating of “Moderate Buy” and an average target price of $49.89.

Insiders Place Their Bets

In other AtriCure news, insider Justin J. Noznesky sold 6,182 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total value of $239,861.60. Following the completion of the transaction, the insider owned 100,219 shares of the company’s stock, valued at $3,888,497.20. This represents a 5.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Sven Wehrwein sold 25,000 shares of AtriCure stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $37.84, for a total value of $946,000.00. Following the sale, the director directly owned 40,518 shares in the company, valued at $1,533,201.12. The trade was a 38.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 53,616 shares of company stock valued at $2,149,994 in the last quarter. 4.00% of the stock is currently owned by insiders.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.